Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.25.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenue $ 200,000   $ 200,000 $ 50,000
Operating expenses:        
Research and development 1,877,000 $ 1,535,000 3,182,000 3,141,000
General and administrative 2,742,000 2,961,000 5,543,000 6,508,000
Total operating expenses 4,619,000 4,496,000 8,725,000 9,649,000
Operating loss (4,419,000) (4,496,000) (8,525,000) (9,599,000)
Other income (expense):        
Interest expense (57,000) (34,000) (114,000) (60,000)
Interest income 112,000 42,000 286,000 97,000
Total other income 55,000 8,000 172,000 37,000
Net loss from continuing operations (4,364,000) (4,488,000) (8,353,000) (9,562,000)
Loss from discontinued operations   (3,723,000)   (4,395,000)
Net loss $ (4,364,000) $ (8,211,000) $ (8,353,000) $ (13,957,000)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.48) $ (2.42) $ (0.94) $ (6.27)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.48) (2.42) (0.94) (6.27)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations 0.00 (2)   (2.88)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations 0.00 (2.00) 0.00 (2.88)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (0.48) (4.42) (0.94) (9.15)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (0.48) $ (4.42) $ (0.94) $ (9.15)
Weighted-average common shares outstanding - basic 9,132 1,856 8,880 1,525
Weighted-average common shares outstanding - diluted 9,132 1,856 8,880 1,525